Advertisement
Table 10 Outcomes for REPORT #2
| Sertraline continuation | Mirtazapine augmentation | Mirtazapine switch | Difference, RR, HR (95 % CI), P value, and adjusted 1, 2, | Difference | Difference | |
|---|---|---|---|---|---|---|
| Primary PHQ9 total score, mean, (SD, 95 % CI) | ||||||
| Effect size | ||||||
| Model-based coefficient, P value | ||||||
| Secondary1 FIBSER total score, mean, (SD, 95 % CI) | ||||||
| Effect size | ||||||
| Model-based coefficient, P value | ||||||
| Secondary 2 | ||||||
| … | ||||||
| Secondary 16 | ||||||
| Item 1 n (%) | ||||||
| …. | ||||||
| (Subgroup) | ||||||
| XXXX | ||||||
| Primary | ||||||
| Secondary | ||||||
| …. |
